Lilly raises outlook for third time this year as Zepbound sales soar
MarketWatch· Jaimy Lee· Oct 29, 2026 · 11:19 AM
The GLP-1 drug continues to dominate the market for prescription weight-loss drugs in the U.S.
This is a summary. Read the complete story at MarketWatch below.
Read full article at MarketWatchRelated Stories
marketsabout 2 hours ago
Micron’s stock is dirt cheap — and that’s igniting a fierce online debate
Valuation purists see a ridiculously inexpensive stock, but some semiconductor investors say Micron’s earnings power won’t hold up.
MarketWatch
marketsabout 3 hours ago
A disturbing employment trend is hiding beneath the latest strong job numbers
The average jobless worker's bout of unemployment surpassed 27 weeks in October, the highest outside of the pandemic period in a decade.
CNBC Markets
marketsabout 4 hours ago
My adviser recommended an annuity. Is it the right move in this market environment?
“I haven’t committed to the strategy yet and would appreciate some independent perspectives.”
MarketWatch